Exelixis, Inc. (EXEL) Stake Increased by Swiss National Bank

Swiss National Bank grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 8.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 486,900 shares of the biotechnology company’s stock after buying an additional 38,500 shares during the quarter. Swiss National Bank owned 0.17% of Exelixis worth $11,992,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Legal & General Group Plc increased its position in shares of Exelixis by 1.3% in the first quarter. Legal & General Group Plc now owns 84,763 shares of the biotechnology company’s stock valued at $1,834,000 after buying an additional 1,078 shares in the last quarter. Aperio Group LLC increased its position in shares of Exelixis by 2.7% in the second quarter. Aperio Group LLC now owns 58,345 shares of the biotechnology company’s stock valued at $1,437,000 after buying an additional 1,514 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Exelixis by 7.0% in the second quarter. Teacher Retirement System of Texas now owns 23,251 shares of the biotechnology company’s stock valued at $573,000 after buying an additional 1,517 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Exelixis by 14.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,751 shares of the biotechnology company’s stock valued at $320,000 after buying an additional 1,838 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its position in shares of Exelixis by 26.6% in the second quarter. Meeder Asset Management Inc. now owns 9,957 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 2,091 shares in the last quarter. Institutional investors and hedge funds own 79.20% of the company’s stock.

Shares of Exelixis, Inc. (NASDAQ EXEL) opened at 26.95 on Wednesday. Exelixis, Inc. has a 12 month low of $10.04 and a 12 month high of $29.50. The company’s 50 day moving average price is $27.11 and its 200 day moving average price is $23.26. The stock has a market capitalization of $7.92 billion, a PE ratio of 136.11 and a beta of 1.97.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company’s quarterly revenue was up 173.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) EPS. Equities analysts anticipate that Exelixis, Inc. will post $0.26 earnings per share for the current fiscal year.

WARNING: This article was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/09/13/exelixis-inc-exel-stake-increased-by-swiss-national-bank.html.

A number of research firms have recently commented on EXEL. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of Exelixis in a research report on Tuesday. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Exelixis in a research report on Sunday. Piper Jaffray Companies restated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Sunday. Stifel Nicolaus restated a “hold” rating and issued a $26.00 price objective on shares of Exelixis in a research report on Thursday, September 7th. Finally, BidaskClub upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 25th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $25.82.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply